Louise Chen
Stock Analyst at Scotiabank
(3.43)
# 985
Out of 5,124 analysts
300
Total ratings
47.72%
Success rate
4.33%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $31.21 | +12.14% | 4 | Dec 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $45 → $53 | $53.94 | -1.74% | 1 | Dec 4, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $105.26 | +14.00% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $771.87 | -0.24% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $21.52 | +271.75% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $3.01 | +199.00% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $24.82 | -43.58% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $3.22 | +272.67% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.99 | +175.14% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $75.96 | -27.59% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.75 | +445.45% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $104.67 | -52.23% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.83 | +157.29% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $35.52 | -52.14% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.13 | -2.95% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $19.56 | +155.62% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $11.65 | +157.51% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $17.64 | +211.79% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.33 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $50.88 | +214.47% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $46.14 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $228.49 | +5.04% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $24.90 | +80.72% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $206.95 | +3.89% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.96 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.70 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,074.68 | -17.65% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.65 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $25.42 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.04 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.08 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $220.89 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.59 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.42 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.96 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.77 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.63 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.51 | +1,751.85% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.82 | +77.30% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $13.33 | +275.09% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $29.04 | +72.18% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.63 | +206.75% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.58 | +1,451.46% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $0.93 | +181,217,683.51% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $290.19 | -11.09% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.30 | +3,746.15% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.26 | +1,487.30% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.71 | +483.66% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $31.21
Upside: +12.14%
Bristol-Myers Squibb Company
Dec 4, 2025
Maintains: Sector Perform
Price Target: $45 → $53
Current: $53.94
Upside: -1.74%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $105.26
Upside: +14.00%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $771.87
Upside: -0.24%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $21.52
Upside: +271.75%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $3.01
Upside: +199.00%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $24.82
Upside: -43.58%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.22
Upside: +272.67%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.99
Upside: +175.14%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $75.96
Upside: -27.59%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.75
Upside: +445.45%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $104.67
Upside: -52.23%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.83
Upside: +157.29%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $35.52
Upside: -52.14%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.13
Upside: -2.95%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $19.56
Upside: +155.62%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $11.65
Upside: +157.51%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $17.64
Upside: +211.79%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.33
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $50.88
Upside: +214.47%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $46.14
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $228.49
Upside: +5.04%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.90
Upside: +80.72%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $206.95
Upside: +3.89%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.96
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.70
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,074.68
Upside: -17.65%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.65
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $25.42
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.04
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.08
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $220.89
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.59
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.42
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.96
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.77
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.63
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.51
Upside: +1,751.85%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.82
Upside: +77.30%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $13.33
Upside: +275.09%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $29.04
Upside: +72.18%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.63
Upside: +206.75%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.58
Upside: +1,451.46%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $0.93
Upside: +181,217,683.51%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $290.19
Upside: -11.09%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.30
Upside: +3,746.15%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.26
Upside: +1,487.30%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.71
Upside: +483.66%